Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy ; volume:12 ; number:1 ; day:12 ; month:3 ; year:2019 ; pages:1-11 ; date:12.2019
Journal of hematology & oncology ; 12, Heft 1 (12.3.2019), 1-11, 12.2019
- Urheber
-
Qin, Shuang
Li, Anping
Yi, Ming
Yu, Shengnan
Zhang, Mingsheng
Wu, Kongming
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-019-0718-5
- URN
-
urn:nbn:de:101:1-2019040700594263174793
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Qin, Shuang
- Li, Anping
- Yi, Ming
- Yu, Shengnan
- Zhang, Mingsheng
- Wu, Kongming
- SpringerLink (Online service)
Ähnliche Objekte (12)
3D tumor angiogenesis models: recent advances and challenges
Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
Recent advances in pharmacological diversification of Src family kinase inhibitors
Editorial: Targeting bruton tyrosine kinase
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Auto-thiophosphorylation activity of Src tyrosine kinase
3D tumor angiogenesis models: recent advances and challenges
Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
Recent advances in pharmacological diversification of Src family kinase inhibitors
Editorial: Targeting bruton tyrosine kinase
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Auto-thiophosphorylation activity of Src tyrosine kinase
3D tumor angiogenesis models: recent advances and challenges
Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
Recent advances in pharmacological diversification of Src family kinase inhibitors
Editorial: Targeting bruton tyrosine kinase
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status